Drugs / XELAFASLATIDE
XELAFASLATIDE
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05160805 | May 2022 → Apr 2024 | open-angle glaucoma | ONL Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04744662 | Jul 2021 → Feb 2024 | diffuse secondary choroid atrophy | ONL Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06659445 | Oct 2025 → Nov 2028 expected | dry age related macular degeneration | ONL Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT05730218 | Apr 2023 → Feb 2024 | rhegmatogenous retinal detachment | ONL Therapeutics | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03780972 Comparator | Oct 2019 → Aug 2021 | rhegmatogenous retinal detachment | ONL Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-12-09 | ONL Therapeutics | Results ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science onltherapeutics.com ↗
Published data from the Phase 1b study demonstrated xelafaslatide to be generally safe and well tolerated. |
| 2023-02-01 | ONL Therapeutics | Regulatory ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution onltherapeutics.com ↗
today announced the U.S. Food and Drug Administration (FDA) has authorized the company to proceed with the Investigational New Drug (IND) application for ONL1204 Ophthalmic Solution, a first-in-class small molecule Fas inhibitor designed as a neuroprotectant for key retinal cells. |
All press releases naming this drug 11 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XELAFASLATIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068318 ↗ |
| Known as | ONL1204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06659445 ↗ |
| Known as | Xelafaslatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068318 ↗ |
| Action | Inhibit | “inhibitor of Fas(CD95) signaling” NCT03780972 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068318 ↗ |
| Route | Intravitreal | “by intravitreal injection” NCT03780972 ↗ |